Atara Biotherapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 225
- Market Cap
- $33.6M
- Website
- http://www.atarabio.com
- Introduction
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Clinical Trials
20
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT06429800
- Locations
- 🇺🇸
Atara Biotherapeutics, Thousand Oaks, California, United States
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT06256484
- Locations
- 🇺🇸
AdventHealth Cancer Institute, Orlando, Florida, United States
🇺🇸Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
- Conditions
- Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative DisordersAllogeneic Hematopoietic Cell TransplantStem Cell Transplant ComplicationsEBV+ Sarcomas
- Interventions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT04554914
- Locations
- 🇺🇸
University of California Los Angeles (UCLA) (Adults and Pediatrics), LOS Angeles, California, United States
🇺🇸Children's Hospital of Orange County (Pediatrics [up to 25 years old]), Orange, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford (Pediatrics only), Palo Alto, California, United States
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Conditions
- Epstein-Barr ViraemiaNasopharyngeal NeoplasmsEpstein-Barr Virus InfectionsNasopharyngeal CarcinomaEpstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03769467
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
- Conditions
- Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
- Interventions
- Biological: ATA188Drug: Placebo
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03283826
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Kaiser Permanente MS Clinic Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
- Prev
- 1
- 2
- Next
News
CMV Treatment Pipeline Expands with 20+ Therapies from Leading Pharmaceutical Companies
DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.
FDA Rejects ImmunityBio's Expanded Anktiva Application While Lifting Hold on Atara's Ebvallo Trials
ImmunityBio received an FDA "refusal to file" letter for its application to expand Anktiva's use in bladder cancer patients, causing a 25% stock plunge and prompting calls for agency clarification.
Atara Biotherapeutics Secures $16 Million Funding to Advance Tab-cel BLA Approval
Atara Biotherapeutics has priced a $16 million offering of common stock and pre-funded warrants to institutional investors including Adiumentum Capital Management and EcoR1 Capital.
FDA Issues Warning to Sanofi for API CGMP Deviations; Clinical Hold Placed on Atara Biotherapeutics
The FDA issued a warning letter to Sanofi, citing significant deviations from CGMP standards at its Genzyme facility, potentially leading to regulatory actions.
Atara Biotherapeutics Navigates Regulatory Hurdles and Financial Uncertainty
Atara Biotherapeutics faces an FDA clinical hold on ATA3219 and EBVALLO due to manufacturing issues, delaying product sales and increasing perceived risk.
FDA Approves Novel Combination Therapies for Colorectal Cancer and Mantle Cell Lymphoma
The FDA has approved sotorasib in combination with panitumumab for treating KRAS G12C-mutated metastatic colorectal cancer in adults who have received specific prior chemotherapy regimens.
FDA Places Clinical Hold on Atara Biotherapeutics' Cell Therapy Programs Due to Manufacturing Concerns
The FDA has placed a clinical hold on Atara Biotherapeutics' EBVALLO (tabelecleucel) program and ATA3219, pausing new patient enrollment.
Tabelecleucel Shows Sustained Efficacy in EBV+ PTLD, FDA Decision Expected in January 2025
Tabelecleucel demonstrates a 50.7% objective response rate in patients with relapsed or refractory EBV+ PTLD after transplant, according to Phase 3 ALLELE study results.
Gene and Cell Therapies Show Promise in Treating CNS Disorders
The market for gene and cell therapies targeting CNS disorders was valued at approximately USD 1 billion in 2021 and is projected to grow significantly by 2034.
Cell Therapy and Targeted Therapies Dominate Oncology Advances in Early 2025
The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.